

# Mitchell Kamrava

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8016187/publications.pdf>

Version: 2024-02-01

95  
papers

1,401  
citations

361413

20  
h-index

395702

33  
g-index

95  
all docs

95  
docs citations

95  
times ranked

2053  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2020, 10, 220-234.	2.1	144
2	Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer. <i>Cancer</i> , 2016, 122, 447-455.	4.1	123
3	Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. <i>European Urology</i> , 2017, 71, 766-773.	1.9	83
4	Brachytherapy in the treatment of cervical cancer: a review. <i>International Journal of Women's Health</i> , 2014, 6, 555.	2.6	80
5	Brachytherapy Training Survey of Radiation Oncology Residents. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 557-560.	0.8	77
6	Evaluation of Mobile Health Applications to Track Patient-Reported Outcomes for Oncology Patients: A Systematic Review. <i>Advances in Radiation Oncology</i> , 2021, 6, 100576.	1.2	42
7	Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1154-1161.	1.3	35
8	Underutilization of brachytherapy and disparities in survival for patients with cervical cancer in California. <i>Gynecologic Oncology</i> , 2018, 150, 73-78.	1.4	35
9	Distortion-free diffusion MRI using an MRI-guided Tri-Cobalt 60 radiotherapy system: Sequence verification and preliminary clinical experience. <i>Medical Physics</i> , 2017, 44, 5357-5366.	3.0	31
10	American Brachytherapy Society consensus report for accelerated partial breast irradiation using interstitial multicatheter brachytherapy. <i>Brachytherapy</i> , 2017, 16, 919-928.	0.5	31
11	The American Brachytherapy society consensus statement for skin brachytherapy. <i>Brachytherapy</i> , 2020, 19, 415-426.	0.5	28
12	Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation. <i>BMC Cancer</i> , 2016, 16, 556.	2.6	27
13	SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. <i>Practical Radiation Oncology</i> , 2016, 6, 268-275.	2.1	27
14	Outcomes of Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation Via Multicatheter Interstitial Brachytherapy: The Pooled Registry of Multicatheter Interstitial Sites (PROMIS) Experience. <i>Annals of Surgical Oncology</i> , 2015, 22, 404-411.	1.5	26
15	Focal high-dose-rate brachytherapy: A dosimetric comparison of hemigland vs. conventional whole-gland treatment. <i>Brachytherapy</i> , 2013, 12, 434-441.	0.5	25
16	Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer. <i>Practical Radiation Oncology</i> , 2015, 5, 411-416.	2.1	25
17	American Brachytherapy Society recurrent carcinoma of the endometrium task force patterns of care and review of the literature. <i>Brachytherapy</i> , 2017, 16, 1129-1143.	0.5	25
18	The American Brachytherapy Society consensus statement for electronic brachytherapy. <i>Brachytherapy</i> , 2019, 18, 292-298.	0.5	23

#	ARTICLE	IF	CITATIONS
19	The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes. <i>Gynecologic Oncology</i> , 2020, 159, 607-610.	1.4	23
20	Quantitative multiparametric MRI in uveal melanoma: increased tumor permeability may predict monosomy 3. <i>Neuroradiology</i> , 2015, 57, 833-840.	2.2	22
21	Potential role of ultrasound imaging in interstitial image based cervical cancer brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2014, 2, 223-230.	0.9	20
22	Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. <i>Brachytherapy</i> , 2017, 16, 1106-1112.	0.5	19
23	American Brachytherapy Society working group report on the patterns of care and a literature review of reirradiation for gynecologic cancers. <i>Brachytherapy</i> , 2020, 19, 127-138.	0.5	19
24	Socioeconomic and Racial Determinants of Brachytherapy Utilization for Cervical Cancer: Concerns for Widening Disparities. <i>JCO Oncology Practice</i> , 2021, 17, e1958-e1967.	2.9	19
25	High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2017, 16, 299-305.	0.5	18
26	NEW ULTRA-WIDE-FIELD ANGIOGRAPHIC GRADING SCHEME FOR RADIATION RETINOPATHY AFTER IODINE-125 BRACHYTHERAPY FOR UVEAL MELANOMA. <i>Retina</i> , 2018, 38, 2415-2421.	1.7	16
27	Quantifying the Ki-67 Heterogeneity Profile in Prostate Cancer. <i>Prostate Cancer</i> , 2013, 2013, 1-5.	0.6	15
28	Locoregional recurrence by molecular subtype after multicatheter interstitial accelerated partial breast irradiation: Results from the Pooled Registry Of Multicatheter Interstitial Sites research group. <i>Brachytherapy</i> , 2016, 15, 788-795.	0.5	14
29	Head and neck cancer reirradiation with interstitial high-dose-rate brachytherapy. <i>Head and Neck</i> , 2018, 40, 1524-1533.	2.0	14
30	Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines. <i>Scientific Reports</i> , 2019, 9, 2111.	3.3	14
31	Glaucoma After Iodine-125 Brachytherapy for Uveal Melanoma: Incidence and Risk Factors. <i>Journal of Glaucoma</i> , 2020, 29, 1-10.	1.6	14
32	Early clinical outcomes of ultrasound-guided CT-planned high-dose-rate interstitial brachytherapy for primary locally advanced cervical cancer. <i>Brachytherapy</i> , 2015, 14, 626-632.	0.5	13
33	Proposed brachytherapy recommendations (practical implementation, indications, and dose) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10</i>	0.5	13
34	Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. <i>PLoS ONE</i> , 2021, 16, e0252665.	2.5	13
35	Multiparametric MRI identifies and stratifies prostate cancer lesions: Implications for targeting intraprostatic targets. <i>Brachytherapy</i> , 2014, 13, 292-298.	0.5	12
36	Tumor-height regression rate after brachytherapy between choroidal melanoma gene expression profile classes: effect of controlling for tumor height. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 1371-1378.	1.9	12

#	ARTICLE	IF	CITATIONS
37	Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 133-138.	0.6	12
38	External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1045-1052.	0.8	12
39	Long term results from a prospective database on high dose rate (HDR) interstitial brachytherapy for primary cervical carcinoma. <i>Gynecologic Oncology</i> , 2017, 144, 21-27.	1.4	12
40	23-mm iodine-125 plaque for uveal melanoma: benefit of vitrectomy and silicone oil on visual acuity. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2016, 254, 2461-2467.	1.9	11
41	Juxtapapillary and circumpapillary choroidal melanoma: globe-sparing treatment outcomes with iodine-125 notched plaque brachytherapy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2017, 255, 1843-1850.	1.9	11
42	Prediction of soft tissue sarcoma response to radiotherapy using longitudinal diffusion MRI and a deep neural network with generative adversarial network-based data augmentation. <i>Medical Physics</i> , 2021, 48, 3262-3372.	3.0	11
43	Clinical outcomes using image-guided interstitial brachytherapy for definitive cervical cancer patients with high-risk clinical target volumes greater than 30Åcc. <i>Brachytherapy</i> , 2018, 17, 392-398.	0.5	9
44	Paid Parental Leave Policies Among U.S. News & World Report 2020-2021 Best Hospitals and Best Hospitals for Cancer. <i>JAMA Network Open</i> , 2021, 4, e218518.	5.9	9
45	Dosimetric feasibility of magnetic resonance imaging-guided tri-cobalt 60 preoperative intensity modulated radiation therapy for soft tissue sarcomas of the extremity. <i>Practical Radiation Oncology</i> , 2015, 5, 350-356.	2.1	8
46	Interstitial brachytherapy for gynecologic malignancies: Complications, toxicities, and management. <i>Brachytherapy</i> , 2021, 20, 995-1004.	0.5	8
47	A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138432.	5.9	8
48	Does the addition of targeted prostate biopsies to standard systemic biopsies influence treatment management for radiation oncologists?. <i>BJU International</i> , 2016, 117, 584-591.	2.5	6
49	Predicting the necessity of adding catheters to intracavitary brachytherapy for women undergoing definitive chemoradiation for locally advanced cervical cancer. <i>Brachytherapy</i> , 2018, 17, 935-943.	0.5	6
50	A proposal for a new classification of "unfavorable risk criteria" in patients with stage I endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1086-1093.	2.5	6
51	High-dose-rate fractionated brachytherapy monotherapy for localized prostate cancer: a systematic review and meta-analysis. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 365-372.	0.9	6
52	Red Blood Cell Transfusion Practices for Patients With Cervical Cancer Undergoing Radiotherapy. <i>JAMA Network Open</i> , 2021, 4, e213531.	5.9	6
53	Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy. <i>British Journal of Radiology</i> , 2015, 88, 20150658.	2.2	5
54	A dosimetric evaluation of a single urethral constraint for high-dose-rate prostate brachytherapy. <i>Brachytherapy</i> , 2020, 19, 216-221.	0.5	5

#	ARTICLE	IF	CITATIONS
55	Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics. <i>Oncology</i> , 2021, 35, 119-125.	0.5	5
56	ACR's ABS's ASTRO practice parameter for the performance of radionuclide-based high-dose-rate brachytherapy. <i>Brachytherapy</i> , 2021, 20, 1071-1082.	0.5	5
57	Comparison of patient-reported acute urinary and sexual toxicity scores in a 6-versus 2-fraction course of high-dose-rate prostate brachytherapy monotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 109-115.	1.8	4
58	Outcomes of Node-positive Breast Cancer Patients Treated With Accelerated Partial Breast Irradiation Via Multicatheter Interstitial Brachytherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 538-543.	1.3	4
59	Outcomes with multi-disciplinary management of central lung tumors with CT-guided percutaneous high dose rate brachyablation. <i>Radiation Oncology</i> , 2021, 16, 99.	2.7	4
60	American Brachytherapy Society (ABS) consensus statement for soft-tissue sarcoma brachytherapy. <i>Brachytherapy</i> , 2021, 20, 1200-1218.	0.5	4
61	SABR as an Alternative Boost Modality for Cervical Cancer: A Cautionary Exercise. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 472-474.	0.8	4
62	Quantitative Nodal Burden and Mortality Across Solid Cancers. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1003-1011.	6.3	4
63	Another solution that enables ablative radiotherapy for large liver tumors: Percutaneous interstitial high-dose rate brachytherapy. <i>Cancer</i> , 2016, 122, 2766-2766.	4.1	3
64	Interstitial high-dose-rate brachytherapy in the treatment of keloids: Moving toward a volumetric approach. <i>Brachytherapy</i> , 2021, 20, 185-188.	0.5	3
65	Hypofractionated radiation therapy and wound healing after massive sarcoma resection: Case report and review of the literature. <i>International Journal of Surgery Case Reports</i> , 2021, 83, 106005.	0.6	3
66	Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy. <i>World Journal of Gastrointestinal Surgery</i> , 2020, 12, 377-389.	1.5	3
67	American Brachytherapy Society radiation oncology alternative payment model task force: Quality measures and metrics for brachytherapy. <i>Brachytherapy</i> , 2022, 21, 63-74.	0.5	3
68	Re: Ian A. Donaldson, Roberto Alonzi, Dean Barratt, et al. Focal Therapy: Patients, Interventions, and Outcomes—A Report from a Consensus Meeting. <i>Eur Urol</i> 2015;67:771-777. <i>European Urology</i> , 2015, 68, e14.	1.9	2
69	In Regard to Mishra et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 216.	0.8	2
70	Intensity modulated radiation therapy for women with gynecologic cancers: this horse is also already out of the barn. <i>Gynecologic Oncology</i> , 2016, 143, 1-2.	1.4	2
71	Prostate Cancer Radiotherapy: An Evolving Paradigm That Should Also Include High-Dose-Rate Monotherapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 441-441.	1.6	2
72	Evaluation of sociodemographic and baseline patient characteristic differences in cervical cancer patients treated with either external beam or brachytherapy boost. <i>Brachytherapy</i> , 2022, 21, 22-28.	0.5	2

#	ARTICLE	IF	CITATIONS
73	Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 153-158.	2.5	2
74	A sector-based dosimetric analysis of dose heterogeneity in high-dose-rate prostate brachytherapy. <i>Brachytherapy</i> , 2015, 14, 173-178.	0.5	1
75	The ideal adjuvant treatment in node positive vulvar cancer is (fill in your best guess here). <i>Gynecologic Oncology</i> , 2015, 137, 363-364.	1.4	1
76	Real-time image guidance for gynecologic brachytherapy?. <i>Radiotherapy and Oncology</i> , 2016, 120, 542-543.	0.6	1
77	Enhanced skin toxicity with concurrent ipilimumab and radiation in vaginal/vulvar melanoma: a case report and literature review. <i>BJR   case Reports</i> , 2017, 3, 20160002.	0.2	1
78	In Regard to Peters et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1182-1183.	0.8	1
79	Letter to the Editor Regarding: Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation with Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy. <i>Practical Radiation Oncology</i> , 2019, 9, 59.	2.1	1
80	Evaluating reimbursement of skin radiation therapy: Technique and fractionation. <i>Brachytherapy</i> , 2020, 19, 700-704.	0.5	1
81	Clinical Development and Evaluation of Megavoltage Topogram for Fast Patient Alignment on Helical Tomotherapy. <i>Advances in Radiation Oncology</i> , 2020, 5, 1334-1341.	1.2	1
82	Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer. <i>Anticancer Research</i> , 2017, 37, 1237-1242.	1.1	1
83	Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 511-524.	2.0	1
84	Evaluation of burnout in physician members of the American Brachytherapy Society. <i>Brachytherapy</i> , 2022, 21, 362-368.	0.5	1
85	In Regard to Apisarnthanarax et al. <i>Practical Radiation Oncology</i> , 2022, 12, e239.	2.1	1
86	An evaluation of gender diversity in the American Brachytherapy Society. <i>Brachytherapy</i> , 2019, 18, 835-840.	0.5	0
87	Preoperative CA 19-9 and CEA as predictors of operative outcomes in resectable gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e15581-e15581.	1.6	0
88	Impact of palliative care in patients with metastatic esophageal cancer declining chemotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 315-315.	1.6	0
89	The impact of neoadjuvant and/or adjuvant treatment modalities in resectable gastric cancer (rGC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e16564-e16564.	1.6	0
90	Baseline features predicting receipt of chemotherapy in metastatic esophageal cancer: A National Cancer Database analysis of 12,370 patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 316-316.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Extent of lymph node resection and effect on pancreatic cancer overall survival.. Journal of Clinical Oncology, 2020, 38, 682-682.	1.6	0
92	A radiopaque polymer hydrogel as an irreversible electroporation compatible fiducial marker for pancreas stereotactic body radiotherapy. Journal of Radiosurgery and SBRT, 2020, 7, 165-167.	0.2	0
93	Re: Jana S. Hopstaken, Joyce G.R. Bomers, Michiel J.P. Sedelaar, Massimo Valerio, Jurgen J. FÃ¼tterer, Maroeska M. Rovers. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? Eur Urol. In press. <a href="https://doi.org/10.1016/j.eururo.2021.08.005">https://doi.org/10.1016/j.eururo.2021.08.005</a> . European Urology, 2021, . . .	1.9	0
94	Driving accountable care with brachytherapy. Brachytherapy, 2022, 21, 4-5.	0.5	0
95	Pathologic primary tumor factors associated with risk of lymph node involvement in patients with non-endometrioid endometrial cancer. Gynecologic Oncology, 2022, . .	1.4	0